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Anne Spaulding, MD
Rhode Island Department of Corrections
"Hepatitis C is found rife among inmates," trum-
peted a recent New York Times article, (1) a
"discovery" that comes as no surprise to cor-
rectional providers, since we’re well aware of
the relationship between drug use, incarcera-
tion, and  hepatitis C (HCV) infection.
Approximately 80% of persons incarcerated in
the US admit to a history of using illegal drugs
and about 1 in 4 have used parenteral drugs
(2). Furthermore, about 4 million non-incarcer-
ated individuals are infected with HCV. Due to
the linkages between drug use, HCV, and incar-
ceration, an estimated 1.4 million persons
affected by HCV, or 30% of the total HCV cases
in the U.S. are believed to pass through correc-
tional facilities each year (3).
The number of incarcerated individuals affected
by HCV is high, regardless of the region of the
country. For example, Texas reported that
42,000 inmates were infected with HCV (28.6%
of the incarcerated population)(1). Other states
also report high infection rates among inmates:
Connecticut (32%) (4), Virginia (30-40%)(5),
Maryland (38%) (6), and California (41%)(7). In
New Jersey, 929 inmates were tested for HCV
in response to evidence of hepatic transami-
nase elevations, or co-infection with hepatitis B
or HIV. 67.3% of these inmates tested positive
for HCV antibody (8). Many states do not for-
mally test for HCV infection in their populations
unless medically indicated (for reasons such as
elevated liver function tests), therefore, current
estimates of the prevalence of HCV infection in
some correctional settings may be artificially
low.
The prevalence of HCV infection in correctional
facilities raises a number of diagnostic and
management dilemmas. Unlike HIV infection,
which currently requires lifelong treatment after
the initiation of therapy, treatment for HCV usu-
ally requires intervention for a limited period of
time. In addition, many of our patients are incar-
cerated for relatively brief (and sometimes hard
to predict) periods of time.  Therefore, it can be
difficult to determine whether an individual
patient will be able to complete the course of
therapy, if it were to be initiated in the correc-
tional setting. 
Debate about the timing and location of the
treatment course and which budget should bear
the cost of treatment (correctional or communi-
ty), further complicates HCV treatment deci-
sions. And now that patients with HIV are living
longer, consideration must be given to treating
chronic conditions like HCV that were consid-
ered irrelevant to HIV management in the pre-
HAART era. Many correctional providers would
probably consider the management of HCV
and HCV/HIV co-infection in the correctional
setting to be their biggest challenge.
 Natural History of HCV Infection
Hepatitis C virus is a member of the flaviviridae
family. Infection is blood borne, and therefore
can be associated with injection drug use, tat-
tooing, and needle stick injuries (9). Infection
was formerly associated with blood transfusion,
until screening for HCV was initiated (1989) and
new methods for detecting HCV reduced the
risk of HCV transmission by blood products to 1
in 100,000 units. 
About 15% of HCV exposed patients resolve
their infection without sequellae, while approxi-
mately 85% of cases eventually develop chron-
ic hepatitis and persistent although occasional-
ly intermittent, viremia(10). Infection results in
the development of closely related yet hetero-
geneous populations of viral genomes (quasi
species). Probably as a result of this genetic
diversity, HCV evades the host immune
response, leading to a high rate of chronic
infection. Persons with chronic HCV are often
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HEPP News, a forum for correctional
problem solving, evolved out of ongoing dis-
cussions among HIV specialists based at the
Brown University AIDS Program about the
need for HIV updates designed for practition-
ers in the correctional setting. The board of
editors includes national and regional correc-
tional professionals, selected on the basis of
their experience with HIV care in the correc-
tional environment and their familiarity with
current HIV treatment. HEPP News targets
correctional administrators and HIV/AIDS
care providers including physicians, nurses,
outreach workers and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering such treat-
ments in the correctional environment,
national and international news related to
HIV in prisons and jails, and correctional
trends that impact HIV treatment. Continuing
Medical Education credits are provided by
the Brown University Office of Continuing
Medical Education to physicians who accu-
rately respond to the questions on the last
page of the newsletter; please see last page
for details.
The editorial board and contributors to
HEPP News are well aware of the critical role
prisons and jails play in the treatment and
prevention of HIV. The goal of HEPP News is
to provide reports of effective and cost-con-
scious HIV care that can truly be implement-
ed within the correctional environment. We
hope this newsletter achieves that goal.
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asymptomatic but have the capacity to infect others.  HCV can lead
to cirrhosis and liver failure (20% of chronic HCV infections). In peo-
ple who are co-infected, HIV may cause HCV to advance more
quickly; they have a 12 to 300 fold higher risk of developing hepato-
cellular carcinoma than non-carriers (10). HCV is  responsible for
approximately 40% of the 25,000 annual deaths from chronic liver
disease in the U.S. (9). 
 Diagnosis of HCV
Tests that detect antibody against the virus include the enzyme
immunoassay (EIA) and the recombinant immunoblot assays
(RIBA). The EIA test is suitable for screening for HCV infection. RIBA
is used to confirm an EIA result in a low risk population if a positive
result is suspected to be a false positive; it probably has little use in
a correctional setting. The polymerase chain reaction assay for HCV
(RT-PCR) enables direct quantification of the virus in the blood (sim-
ilar to the HIV viral load assay). A positive RT-PCR is definitive proof
of HCV infection. RT-PCR can be used to quantify virus in the course
of infection; however, there is variability between laboratories, so cli-
nicians should use the same laboratory to evaluate a patient at
sequential time points. Liver biopsy can demonstrate the extent of
liver injury. Many gastroenterologists are now questioning the need
for routine biopsy in all HCV patients before treatment.
 Treatment Options
In 1997, the National Institutes of Health Consensus Committee rec-
ommended treatment of HCV infection with 3 million units of inter-
feron (aIFN) subcutaneously three times a week for 12 months. The
1997 consensus statement, which includes extensive discussions of
the natural history of HCV, diagnosis, and treatment, can be found at
the following internet website: http://odp.od.nih.gov/
consensus/statements/cdc/105/105_stmt.html/ 
Recent studies indicate important considerations when using inter-
feron.  Neutralizing anti-interferon antibodies have been shown to
develop in some patients with chronic HCV receiving treatment with
interferon.  The presence of these antibodies suggests an associa-
tion with a decrease in responsiveness to interferon (11).
Interferon monotherapy remained the standard treatment for HCV
until last year, when the combination of interferon and oral ribavirin
won FDA approval because of its improved efficacy. While ribavirin
has no lasting effect when taken alone, combining 600 milligrams of
ribavirin by mouth twice a day with interferon at 3 million units sub-
cutaneously three times a week leads to a doubling of HCV RNA
clearance (10). Most clinicians now initiate treatment with this form
of combination therapy, rather than using interferon alone.
Interferon effectively cures between 15 to 20% of patients who are
given a one-year course of therapy (9). Combination therapy with
interferon and ribavirin has demonstrated 30 to 50% response rates
(12, 13, 14). Response to combination therapy may even be
observed in patients with advanced HCV infection and cirrhosis (15).
The ideal duration of therapy-6 months versus a year-is still being
determined.  Non-responders to interferon monotherapy can be
identified early by assessing the serum ALT level and the presence
of serum HCV RNA after 3 months of therapy. If the ALT level
remains abnormal, and the serum HCV RNA remains detectable,
interferon therapy should be stopped, because further treatment is
unlikely to produce a response. If the virus is undetectable, continu-
ation of treatment depends on the HCV genotype (which can be
checked before starting therapy). If the virus is genotype 1 (which
represents >70% of the HCV in the U.S.), the therapy should be con-
tinued for another 6 months.  Infection with other genotypes may
only required in the initial 6 months of treatment. Detectable
response may take 4 or 5 months to achieve but those who fail to
respond at 6 months are unlikely ever to respond.
The following features are the most common independent factors
predictable of sustained response to interferon therapy:
  early normalization of ALT levels
  low serum HCV-RNA levels
  HCV genotype other than genotype 1
  mild chronic hepatitis on liver biopsy
  age<45 years (11)
Other interventions that are thought to be helpful for the manage-
ment of HCV include Hepatitis A (HAV) vaccination (16).
Superinfection with HAV may be associated with fulminant liver fail-
ure in HCV patients. 
 Treatment-Associated Side Effects
Interferon side-effects commonly include flu-like symptoms, irritabili-
ty, and depression. Hematological abnormalities such as anemia are
common. Severe adverse effects include severe depression,
seizures, and generalized bacterial infections (<2% of patients
receiving interferon) (11). Decreasing the dosage of interferon may
be helpful; severe side-effects result in the discontinuation of treat-
ment in 5 to 10% of patients. Paradoxical worsening of hepatitis may
also occur, and is thought to be due to an autoimmune response.
Treatment should be discontinued in patients who have rising serum
ALT levels to greater than twice the baseline. Ribavirin can produce
hemolytic anemia, which can be life threatening in patients with heart
disease and cerebral vascular disease. Ribavirin is teratogenic, and
therefore contraindicated in women who are considering becoming
pregnant and their male partners. Sexually active women and men
should use reliable birth control during treatment and for at least 6
months after completion of a ribavirin regime.  A male prisoner leav-
ing prison less than 6 months after treatment ends needs warning
not to impregnate a female partner until risk of teratogenicity has
passed. 
 HIV and HCV Co-infection
Co-infection with HIV further complicates HCV treatment decisions.
Now that HAART has improved the overall prognosis of HIV, viral
hepatitis is destined to become an increasing cause of morbidity and
mortality for many of our HIV and HCV co-infected patients.
While co-infected patients can tolerate interferon therapy (17), few
may respond and those who do may relapse (18, 19), although some
practitioners believe the response rate for HIV and non-HIV infected
patients may not differ (20). In some co-infected patients, CD4 T cell
counts have been observed to plummet on interferon (21). In addi-
tion, previously asymptomatic patients with high CD4 counts who are
started on interferon have developed opportunistic infections such as
Pneumocystis carinnii pneumonia. 
Interactions with anti-retroviral medications should be carefully con-
sidered prior to initiation of therapy. Ribavirin may block the action of
zidovudine (AZT) and stavudine by inhibiting the phosphorylation of
the antiretroviral drug. It does not seem to antagonize didanosine
(ddI) and ribavirin/ddI combinations may even be synergistic (22).
The interaction of ribavirin with all anti-retroviral drugs needs to be
better defined, as few have had experience with combining these
therapies. 
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S A V E T H E D A T E S
1999 National HIV Prevention Conference
August 29 - September 1, 1999
Atlanta, Georgia
For more information, call 404.639.1942, or 
e-mail: 99hivconf@cdc.gov
1999 HCV Global Foundation 3rd Annual HCV
Conference: The World and Hepatitis C
August 21-23, Oakland, California
Contact: Ronald Duffy - HCV Global Foundation
707.425.8862, Fax 707.425.8862 or visit
www.hcvglobal.org
Clinical Trials in the Correctional Setting
Providence, Rhode Island
October 13-15, 1999
Conference will review the practice and legal and
ethical aspects of clinical trials in correctional set-
tings. Will develop practical guidelines from the
perspective of institutions where trials are being
held. Contact Betsy Stubblefield via fax
401.863.1243 or e-mail heppnews@brown.edu
HIV/AIDS Behind Bars
Call for Abstracts.
HEPP News at BRUNAP is sponsoring a pre-con-
ference colloquium on November 7 at the
NCCHC conference listed above that will discuss
public health and corrections collaborations.
Accepting 500 word abstracts addressing this
topic until September 1. Please fax
(401.863.2180) or e-mail (heppnews@brown.
edu) questions to Betsy Stubblefield.
23rd National Conference on Correctional
Health Care  
November 8 - November 10, 1999  
Fort Lauderdale, Florida 
For more information, call 773.880.1460
Fax: 773.880.2424  Or visit: http://www.ncchc.org
1999 ACA 129th Summer Congress of
Correction
August 9-12, 1999
Denver, Colorado
For more information, visit http://www.correc-
tions.com/aca/conference/colorado99/index.html
To register by phone: 1.800.222.5646  ext.1922;
or by fax: 301.918.1900
Dear Colleagues,
In case you were wondering where the newsletter was this month, I have to confess that it went with me to West Africa before it
reached the copy desk, hence the delay.  That said, I’m really pleased with this issue, because it responds to a concern many of
you have voiced in your communications with us.  The main article by Dr. Anne Spaulding of the Adult Correctional Institution in
Rhode Island, gives her perspective on the management of hepatitis C  in the correctional setting. Our guest editor, Lou Tripoli,
provides a counterpoint perspective in his editorial. Other features this month include the Heppigram, suggesting treatment guide-
lines for HCV infection in corrections, and an expert opinion on managing HCV/HIV co-infection by Dr. David Paar of the University
of Texas.  After reading this issue, readers should understand the scope of hepatitis infection in correctional facilities, list the criteria
for HCV treatment in corrections, understand how to adjust the treatment of co-infection, and name which vaccines should be given
to hepatitis-infected patients.
Next month, Faye Duffin of the North Carolina Department of Corrections will discuss nurse case management of HIV infection in
the correctional setting. We will also provide you with some tools for enhancing nursing management. 
Sincerely, 
Anne De Groot, MD
We at Correctional Medical Services are responsible for the health-care of about 300,000 incarcerated individuals in United States.
We have a great deal of information on the prevalence of diseases within the 32 states in which we operate. Chronic liver disease
and cirrhosis rank number 15 on our list of diseases that cause serious medical sequelae.  Coronary artery disease, AIDS, dia-
betes, and a multiplicity of other medical problems consume far more resources and results in far more consequences than hepati-
tis C. 
Why, then, the dramatic new emphasis on hepatitis C in correctional settings?  First, hepatitis C tends to be over represented in the
inmate population as compared to the general population. Second, the pharmaceutical industry has adroitly seized the opportunity
and has been highly successful in driving awareness of hepatitis C both in and outside of correctional institutions. In my opinion, by
aggressively treating hepatitis C, we may end up expending valuable resources providing medication to a large number of people
who may derive no substantial benefit, in order to prevent complications in a minority.  Many of us believe that new therapies will
become available in the future to treat this infection, and that new strategies will emerge to better predict which patients will benefit
from treatment.
I beg my colleagues to pursue a "rational approach to hepatitis C infection," somewhat like the one Dr. Spaulding describes in this
issue.  However, I would be even more conservative in my approach. Much of what we believe about hepatitis comes to us from
content-area specialists, such as hepatologists, few of whom have had any appreciable experience treating a correctional popula-
tion. No long-term studies are available to tell us whether those who are selected for treatment in correctional settings will benefit
from treatment and maintain behaviors that will reduce the chance of future reinfection.
Are we being led down a "primrose path" by the drug companies? Certainly, a great deal of human suffering has been alleviated by
the development of new pharmaceuticals. I have yet to see any of the pharmaceutical companies offer to cut their prices for the
medications that they sell to the prisons for the treatment of hepatitis C.   I have also yet to see any of them make this medication
available to these same people who, when outside of the prison, are unable to get any medications at all.
Given that most people infected with hepatitis C virus had a long interval to wait for the development of cirrhosis, I would hope that
we exercise rationality in the application of the available technology to this infection. We should not discard the scientific and the
rational for the expedient.  Whether we care to recognize it or not, every action we take costs something in the form of missed
opportunity in action we did not take.
Sincerely,
Louis C. Tripoli, MD
Vice President of Medical Affairs
Correctional Medical Services, St. Louis, Missouri
Adjunct Assistant Professor of Medicine
Johns Hopkins University
Dr. Tripoli recommends the following article for further discussion of HCV treatment: Editorial: Making sense of Hepatitis C.  Lancet, 1998
Nov 7.  Please take a moment to write the editors back. Tell us whether HEPP News is working for you and please feel free to
respond to any of the articles or editorials by e-mail to heppnews@brown.edu or fax to Betsy Stubblefield at 401.863.1243.
L E T T E R F R O M T H E E D I T O R
E D I T O R I A L :  A R A T I O N A L A P P R O A C H T O
H E P A T I T I S C  I N F E C T I O N
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Despite these caveats, there is emerging evidence that treating HCV
in HIV co-infected patients may prevent liver failure. Outcomes may
improve further since the recent approval of ribavirin in combination
with interferon as standard initial HCV therapy. An AmFAR spon-
sored study of interferon with or without ribavirin therapy in HIV/HCV
co-infected patients has been on-going since 1998. Anemia, which
causes treatment withdrawals in some HCV-infected patients may be
a significant problem when the combination is used in patients with
HIV especially when HIV, is advanced or AZT is used. Thus, treat-
ment of HCV is now being carefully considered for selected HIV-
infected incarcerated patients. The challenge for the correctional
physician lies in determining whether treatment is appropriate for an
individual patient. 
 Timing and Cost Effectiveness 
HCV cure rates (sustained virologic response) with currently avail-
able regimens remain low, ranging between 15 to 50%, depending
on the treatment (12, 13, 14). The cost of the medication can be as
high as $12,000 per year per patient. Low cure rates and high cost
have led to delays in the initiation of HCV screening programs in cor-
rectional settings, even though screening for and treating HCV has
been shown to be cost-effective in some populations. For older
patients, a 6 month-long treatment was on the scale of other inter-
ventions that the American public would accept.  For young patients,
6 months of treatment maybe cost saving (23). The use of ribavirin
for HCV changes the picture-cost benefit analyses for combination
therapy. Combination therapy is more expensive than interferon alfa
alone, but because it has a higher success rate,  it may be more
cost-effective.   
Careful selection criteria can further improve the cost-effectiveness
of HCV treatment in the correctional setting.  My colleagues and I
have previously shown that a policy of routinely treating appropriate-
ly screened HCV patients with interferon treatment demands only
3% of correctional facility health care budgets (24).  The following
table shows the hepatitis treatment criteria at RI DOC with the addi-
tion of criteria that must be met before adding ribavirin to a regimen. 
Many U.S. inmates may meet the criteria described above and
receive treatment, however, the total number of HCV infected
inmates treated using these criteria will be much lower than the total
number of inmates who have HCV infection. One approach to limit-
ing the impact of HCV screening on correctional budgets might be to
screen only those inmates who would qualify for HCV treatment by 
clinical criteria. Appropriately screening HIV patients for treatment
may reduce HCV treatment costs.
 Conclusion
High HCV infection rates and new guidelines for treatment are forc-
ing difficult decisions in correctional health facilities. In community
settings, clinicians treat HCV infected patients who meet treatment
criteria with combination interferon/ribavirin therapy. Guidelines for
the selection of patients for therapy in correctional settings should be
developed, with the participation of regional public health officials.
Cost-sharing between correctional facilities and public health is a
subject that needs to be explored, particularly if 30% of all people
with HCV in the community cycle through correctional facilities.
Treatment of these individuals to reduce HCV morbidity and mortal-
ity will have broad implications for general public health.
Treatment of HCV infection in HIV infected patients also bears care-
ful consideration. As HAART therapy continues to prolong the lives
Proposed Inclusion Criteria for Hepatitis Treatment in Prisons
Adapted from RI DOC Criteria and California DOC
  Rule out other causes of liver disease (hemochromatosis, Wilson’s
disease, autoimmune hepatitis, and alpha-1 antitripsin deficiency) 
  Hepatitis virus detectable by PCR
  No alcohol or parenteral drug use in preceding 6 months
  Enroll in a substance abuse program if history of drug/alcohol use
  Control of major illnesses, including HIV (CD4 usually > 400 cells/ml) 
  Good control of any psychiatric illness, especially depression
  Length of stay in prison > 15 months from initiation of treatment
 No signs of decompensated liver disease
 Transaminases greater than upper limits of normal
 Platelet count > 75,000
 Hematocrit > 30%, Albumin > 3.5 mg/dl, Creatinine < 1.5 mg/dl, 
INR< 1.2
 Thyroid function tests nl., no elevated autoantibody titers (ANA, AMA)
 Before treatment with ribavirin: No evidence of coronary heart disease.
Birth control, if conception possible (men and women).  Willingness to
submit to monthly pregnancy tests (women).
Hepatitis B (HBV) - Overlooked and Under-treated
The prevalence of chronic HBV (HbSAg positive patients) may be lower
than HCV infection in correctional settings, but it is still a threat. In fact,
HbSAg positivity rates (up to 47%) are considerably higher than in non-
incarcerated populations (5%)(25).
 Vaccination and Screening for HBV
Prisons are an ideal setting for HBV vaccination, although only a few
facilities have adopted CDC guidelines recommending that the following
receive HBV vaccine: exposed personnel, pregnant women, and house-
hold and sexual contacts of HbSAg carriers (26). The CDC has also rec-
ommended HbSAg screening for all pregnant women, and vaccination
is recommended for the household and sexual contacts of HbSAg carri-
er. Correctional facilities can obtain HBV vaccine for free for inmate
patients up until their 19th birthday under a federal program, Vaccines
for Children. Accessibility may differ in each state but providers can
check with local departments of health, which may be willing to consid-
er cost sharing for HBV vaccination for older inmates, depending on the
regions incidence of HBV infection. HBV vaccination has been adopted
in some correctional facilities due to the high rate of infection among
inmates returning to correctional facilities.  In Rhode Island, incidence of
new HBV infection in recidivist women has been demonstrated to be
high: 12 per 100 person years. This year, RI DOC began vaccinating
inmates less than 19 years old (27). HBV vaccination is less effective in
patients who already have HIV infection, thus boosters or higher doses
may be needed (28). 
 Treatment Options for HBV
Interferon at 5 million units subcutaneously for 16 weeks was the first
treatment for chronic HBV infection. New agents for HBV, including
lamivudine (3TC), adefovir (ADV) and famciclovir (Famvir) are in the
process of being evaluated. Each patient should be evaluated for treat-
ment and decisions about treatment should be made on an individual
basis. 
 Treatment of HBV in the Presence of HIV Co-infection
HIV may lessen the liver damage in the HIV/HBV infected patient and
treatment could be less of an issue than with HCV/HIV co-infection. If, in
the future, life expectancy for HIV increases further, even moderate liver
damage in HIV/HBV co-infected patient may need to be addressed,
especially if HBV treatment improves. Whether sequential or combina-
tion therapy is optimal is unclear. Any liver damage at all may be impor-
tant if it will compromise tolerance of anti-retroviral therapy. 
Contributors include:
HEPP Staff and Rob Lyerla, PhD, epidemiologist in the Hepatitis Branch,
National Center for Infectious Diseases, CDC.
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of HIV infected people, providers need to place more importance on
co-morbid conditions. More HIV patients may die from illnesses
other than opportunistic infections. We recommend that all HIV
infected patients receive screening for viral hepatitis antibodies
(but screening does not need to take place during incarceration,
especially if the stay is brief).
Correctional facilities with limited budgets are urged to develop 
guidelines for prioritizing whom will receive HCV therapy. We rec-
ommend that HCV/HIV co-infected patients who have participated
in substance abuse treatment, have an expected duration of incar-
ceration that permit completion of therapy, have stable psychiatric
or medical conditions, have elevated transaminases but normal
hematological parameters, be considered for treatment of hepati-
tis C virus.
continued from page 1
HCV and HIV in the Correctional Setting
HEPPigram A feature of HEPP News providing concise solutions to correctional HIV-related problems.Adapted From: NIH’s Management of HCV http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm
Before Starting Therapy
  Diagnosis suggested by aminotransferase (ALT or AST) elevations.  Confirm using HCV antibody and HCV RNA levels.
  Rule out other causes of increased hepatic transaminases.  Obtain hepatic ultrasound.  At a minimum, obtain iron studies, alpha
fetoprotein level, PPD, hepatic ultrasound, copper levels. 
  Consider a liver biopsy to confirm HCV diagnosis, assess the grade and stage of disease, and rule out other diagnoses. Biopsy
remains controversial as antibody testing, HCV RNA and liver synthetic function assays are probably just as accurate.
  Assess for suitability of therapy and contraindications (stable mental illness, no decompensated cirrhosis, sufficient sentence to
complete therapy)
  Test for HCV genotype (or serotype) to help determine the duration of therapy. 
  Measure CBC, AST, ALT, albumin and prothrombin time to establish a baseline for these values.
  Counsel the patient about the relative risks and benefits of treatment.  Side effects and contraception should be thoroughly dis-
cussed.
During Therapy
  Start therapy with interferon 3 million units by subcutaneous injection thrice weekly plus RBV 1,000 or 1,200 mg p.o. daily (may be
in BID divided doses).
  At weeks 1, 2, and 4 and then at intervals of every 4 to 8 weeks thereafter, assess side effects, symptoms, CBC, PT, albumin and
AST/ALT.
  Adjust the dose of RBV downward (by 200 mg at a time) if significant anemia occurs (Hgb < 10 gm/dL or Hct < 30%) and stop
RBV if severe anemia occurs (Hgb < 8.5 gm/dL or Hct < 26%).
  At 24 weeks, assess HCV RNA levels. If HCV RNA is still present, stop therapy. If patient had genotype 1 (1a or 1b) and HCV
RNA is negative continue therapy for another 24 weeks. If HCV RNA is non-detectable, continue therapy for a total of 48 weeks. For
those with genotypes 2 and 3, stop therapy if HCV RNA is not lowered. Recheck HCV RNA level at the end of treatment.
  Measure thyroid-stimulating hormone levels every 3 to 6 months during therapy.
  Reinforce the need to practice strict birth control during therapy and for 6 months thereafter.
  At the end of therapy, test HCV RNA level to assess whether there is an end-of-treatment response.
After Therapy 
  Measure AST/ALT levels every 2 months for 6 months. In responders, repeat HCV RNA testing 6 months after ending therapy.
  Six months after stopping therapy test for HCV RNA. If HCV RNA is still negative, the chance for a long-term "cure" is excellent;
relapses have rarely been reported after this point.
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A s k  T h e  E x p e r t
W h a t  W o u l d  Y o u  D o ?
Jim is a 38-year old who was diagnosed with HIV in 1989 and with HCV in 1996. After release from prison twelve years ago, he began using
injectable drugs.  He has been clinically diagnosed with depression however has resisted antidepressant therapy or counseling.  Since his
diagnosis, he has started and stopped antiretroviral medications (AZT, d4T, ddI, ddC, 3TC) several times while in the community. Indinavir
was discontinued after one month in 1997 secondary to hyperbilirubinemia. In 1998, he began AZT, 3TC and nevirapine consistently, howev-
er he describes becoming progressively more depressed and bingeing on alcohol. In early 1999, he is incarcerated and reports recent injec-
tion cocaine use and is admitted to your jail and is given his AZT/3TC/nevirapine regimen.
Four weeks after admission, his vital signs are normal and has poor eye contact.  He is noted to have oral thrush.  His abdominal exam
demonstrates a normal liver size (9cm) without evidence of ascites.  Occasional spider telengectasias are noted on his trunk.
Neuropsychiatric evaluation reveals suicidal ideation without active plans. His laboratory studies reveal an HIV-1 RNA of 43,000 copies/mL
and CD4 = 43. His other routine laboratory findings include a WBC=3,600, platelets=40,000, HGB=11.5, MCV=106, ALT=47, AST=39,
PT=13.2 and albumin=3.8.
What is more likely to be an immediate concern for this patient--HIV or HCV? What regimen would you suggest to treat his HIV?  Is he a can-
didate for HCV treatment?
David Paar, MD, 
Assistant Professor of Medicine, 
University of Texas Medical Branch at Galveston
Speakers Bureau: Roche Pharmaceuticals; 
Education Grant:  Merck Immune Response Corp., 
Other Support: Glaxo Wellcome, Pfizer
Before answering the specific questions at the end of the case pres-
entation, I think it would be useful to review the role that psychiatric
disorders play in HIV infection.  Co-morbid mental illness may be a
contraindication to interferon therapy for HCV and is correlated with
poor adherence to antiretroviral therapy. For example, untreated
depression may lead to feelings of hopelessness and despair, or
patients may treat their depression with alcohol and other sub-
stances that can directly lead to poor adherence.  This may lead to
multi-drug resistant HIV and possibly high risk behavior associated
with HIV transmission. I have heard more than one HIV psychiatrist
assert that psychiatric illness is what is driving the HIV epidemic in
the 90s. I think Jim’s psychiatric co-morbid conditions need to be
properly diagnosed and treated as part of his comprehensive HIV
care.
The good news for Jim is that he has three treatable medical con-
ditions:  HIV, HCV and depression.  It is the complexity of this
patient’s co-morbid conditions that create the challenge.  In this
case, he is presenting with late stage HIV infection (CD4<50) which,
left untreated, has a mortality risk of 25% within the next six months.
Jim has no significant evidence of hepatic synthesis dysfunction
and his transaminases are minimally elevated. Therefore, Jim’s
HCV is less problematic at this point and his risk for cirrhosis from
HCV is 10% per decade. An important intervention would be to
carefully reintroduce a potent antiretroviral combination.  If his HIV
is appropriately managed, he may then live long enough to experi-
ence the complications of HCV infection - cirrhosis or hepatocellu-
lar carcinoma.
What regimen would I suggest to treat his HIV?  I would need more
details in order to provide the best answer.  For example, the cur-
rent regimen might be partially effective if, for example, the baseline
HIV-1 RNA was 400,000 copies per ml or greater, in which case the
current viral load would represent a significant reduction (1.0 log) in
response to treatment.  It would also be helpful to know the extent
of exposure to the other nucleosides because these could be recy-
cled if the duration and pattern of drug administration did not pro-
mote clinically significant resistance. For the purposes of this case,
it is likely that this patient has complete resistance to all non-nucle-
oside RTIs because of the rapid resistance that develops to this
class of drugs. He is likely to have a 184 mutation associated with
3TC resistance as well.  The other RTIs are an altogether different
issue and their resistance is dependent on the duration of their pre-
vious use.  His adherence history suggests that he may be able to
recycle one or more of these agents with ddI and d4T being the
least likely to develop resistance rapidly. 
Of course, I’m presuming a lot, and would therefore order a geno-
typic/phenotypic assay to guide therapy. If genotyping were not
available, I would likely use a two protease combination
(RTV+SQV, RTV+IDV, or NFV+SQV) with two or more additional
recycled nucleoside analogues.  Recycled nucleosides that might
be used could be ddI+d4T; if ddI were used, I would consider adding
hydroxyurea one to three months after initiating the regimen in
order to obtain the initial increase in CD4 count that would be blunt-
ed if hydroxyurea were used up front.  If genotyping did not demon-
strate multiple mutations for the class of RTIs, I would use abacavir
as one of the RTIs. This patient would need very close monitoring
as the complex regimen could create multiple side effects that
would need prompt attention in order to sustain this patient on anti-
retroviral therapy.
Is he a candidate for HCV treatment?  Since I’m not an HCV treat-
ment expert, I would consider referring him to a hepatologist for
evaluation.  Such diagnostic measures as quantitative HCV RNA,
liver biopsy for histopathologic examination, and serial hepatic
transaminase determinations would aid in making treatment rec-
ommendations. The combination of interferon with ribavirin has
yielded impressive results in HIV uninfected patients with 50%
achieving sustained remission. Similar studies in HIV infected
patients are in progress.  Until this patient has achieved a remark-
able increase in CD4, it would be unlikely that he would achieve
adequate results with the combination suggesting that immune
reconstitution after HIV treatment would be essential before consid-
ering HCV therapy.  Moreover, Jim would not be a candidate cur-
rently because of his untreated depression.  
In summary, Jim’s depression and substance use need to be
addressed so that he is able to adhere to long-term, effective anti-
retroviral therapy.  If his HIV remains untreated, he will die of com-
plications of HIV in the short term; if he receives effective antiretro-
viral therapy that delays or prevents HIV-related mortality, he will be
at risk for the long term complications of HCV infection.  Designing
an effective antiretroviral regimen will require additional history and
good clinical judgement; resistance assays would be useful in mak-
ing a final decision. Finally, while there are some relative con-
traindications to HCV therapy, Jim may be a candidate for treatment
once his psychiatric illnesses and HIV infection are adequately
treated.
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R e s o u r c e s  /  O p p o r t u n i t i e s
Center for Substance Abuse Treatment’s (CSAT) Comprehensive
Community Treatment Program (CCTP)
CCTP is a "Knowledge Development" initiative, requiring the application
of rigorous evaluation/research methods to develop new knowledge about
approaches to substance abuse treatment, and emphasizing three
aspects of treatment:  1) special populations, 2) integrated substance
abuse treatment, screening, and early intervention in non-traditional set-
tings, and 3) innovative programs.  
Due dates:  9/10/99,  1/10/00, 5/10/00.
The announcement and application materials are available at SAMHSA’s
website:  www.SAMHSA.gov
Contact: NCADI  800.729.6686.  E-mail:  info@health.org
NMAC’s Equal Access Initiative Computer Grants Program
The announcement and further details are available at www.nmac.org.
Or call Peter Velasco at NMAC:  202.483.6622 
or e-mail:  pvelasco@nmac.org.
Hepatitis Education for Inmates and Correctional Staff
Program announcement 99145.  Contact: Linda Moyer at 404.639.2709
or e-mail: Lam1@cdc.gov.  More information is also available at
http://fundingopps2.cos.com/
Technology Translation and Transfer of Effective HIV Behavioral
Interventions. Centers for Disease Control Program Announcement
99089.  Contact:  Robert Kohmescher at 404.639.1914 or e-mail:
rnk1@cdc.gov.
Resources:
Patients’ Guide to HIV Medicines and Guidelines for Their Use
This publication from the National Minority AIDS Council provides clear
and accurate guidelines for the use of HIV medications and also lists
other sources of information on HIV/AIDS.  It is available online at the
AIDS Treatment Information Service (ATIS) website:  www.hivatis.org.
Free copies are also available from HIVATIS at 800.448.0440; 
TTY 888.480.3739.
Internet Resources:
HIV and Corrections-Related:
National AIDS Treatment Advocacy Project:   http://www.natap.org
National Commission on Correctional Health Care:   http://www.ncchc.org
National Library of  Medicine:
http://nlm.nih.gov/pubs/cbm/Hepatitis_C.html NA
Harvard AIDS Institute:  http://www.hsph.harvard.edu/hai/home.html
HCV-Related:
Hepatitis Information Network:  http://www.hepnet.com
HIV & Hepatitis:    http://www.hivandhepatitis.com
Hepatitis Weekly:  http://www.newsfile.com 
Hepatitis C Website:  
http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm
Links to hepatitis websites:  http://www.asf.org/hepatitislinks.html
National Institute of Allergy & Infectious Diseases:
http://www.niaid.nih.gov/dmid/hepcframe.htm
http://www.niaid.nih.gov/dmid/hepatitisc.htm
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New Interferon Reaches Same Blood
Level in Cirrhotic and Non-Cirrhotic
Patients.
An investigational study found that a
longer-lasting term of interferon alfa-2a
(Roferon-A; Hoffman-La Roche, Nutley,
NJ) reaches the same blood levels as non-
cirrhotic patients then administered once-
weekly in cirrhotic patients. Hepatology
1997; Vol 26(3) (Suppl-1).
Mandatory Inmate HIV Testing Rejected 
A proposal that would make HIV testing
mandatory in Maine correctional institutions
was rejected by the State Senate by a vote
of 21-13.  A Bar Harbor legislator and nurse,
Jill M. Goldthwait, said hospitals do not
require the procedure and neither should
prisons. According to Sen. John W. Benoit,
(R) the concept is not recommended by the
National Centers for Disease Control
because it is not based on risk factors and
the idea could create a false sense of secu-
rity. (June 6, 1999. Bangor News)
Viral Reservoirs: Two Studies Confirm
HIV Persistence Despite HAART 
Two new studies (Zhang et al., Furtado et
al, NEJM 5/27/99) add to the growing evi-
dence that even when highly active anti-
retroviral therapy (HAART) pushes HIV to
undetectable levels, the virus hides in the
body and continues to replicate. 
News Flashes 
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through
September 15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Each of the following patients has chronic hepatitis C with anti-HCV
and HCV RNA in serum and liver biopsy showing chronic hepatitis.
Indicate which of the following individuals would be reasonable candi-
dates for alpha interferon therapy.
Y/N  69-year old renal transplant with abnormal ALT levels (105 U/L), 
18 month sentence.  
Y/N  25 year old injection drug user who has no history of drug rehabili-
tation and will be released in two months.
Y/N  30 year old HIV infected individual with CD4< 250 cells/mL, two 
year sentence.
Y/N  30 year old with normal thyroid function tests, sentence 16 
months, absence of advanced cirrhosis on liver biopsy.
2. The recommended dose of alpha interferon and oral ribavirin therapy
for chronic hepatitis C is:
a) 600 mg ribavirin orally twice a day and 3 million units IFN subcuta-
neously three times a week.
b) 400 mg ribavirin orally twice a day and 5 million units IFN subcuta-
neously three times a week.
c) 600 mg ribavirin orally twice a day and 3 thousand units IFN subcu-
taneously three times a week.
d) 600 mg ribavirin orally and 3 million units IFN subcutaneously daily.
3. The appropriate means of documenting a long-term response to alpha
interfeon therapy of chronic hepatitis C is:  
a) liver biopsy at the end of treatment
b) testing for aminotransferase and HCV RNA at the end of treatment.
c) Liver biopsy done 6 to 12 months after stopping treatment
d) Serum testing for aminotransferases and HCV RNA 6-12 months 
after stopping treatment.
4. Recommendations  to patients co-infected with HIV and chronic hepati-
tis C should include:
a) have sexual partner(s) checked for anti-HCV
b) avoid taking ddI/ribavirin
c) receive hepatitis A vaccine
d) receive hepatitis B vaccine
e) a, c and d
f) all of the above
5. A patient infected with HCV genotype 1 is checked after 6 months of
combination therapy for HCV aminotransferases.  No virus is detected
and transferases are normal. Therapy should be stopped.
a) Yes, because if the virus is undetectable, therapy can be considered 
complete.
b) No.  Because the patient has HCV genotype 1, therapy needs to be 
continued.
6. The CDC has recommended hepatitis B  vaccine for the following indi-
viduals:
a) all pregnant women
b) household and sexual contacts of HbSAg positive individuals
c) exposed personnel
d) persons co-infected with HIV and HCV
e) a,b and c
f) all of the above
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The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continu-
ing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
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HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
resources 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
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